Celldex Therapeutics Inc. | Mutual Funds
Mutual Funds that own Celldex Therapeutics Inc.
Columbia Acorn Fund
7,655,252
4.71%
0
0.07%
03/29/2018
Vanguard Total Stock Market Index Fund
3,249,146
2%
0
0%
07/31/2018
iShares Nasdaq Biotechnology ETF
1,877,279
1.15%
-24,549
0.01%
09/06/2018
Vanguard Extended Market Index Fund
1,798,645
1.11%
5
0%
07/31/2018
PZU FIO Parasolowy - Energia Medycyna Ekologia
1,509,300
0.93%
59,300
0.89%
06/30/2017
DFA US Targeted Value Portfolio
795,355
0.49%
291,117
0%
04/30/2018
DFA US Micro Cap Portfolio
770,480
0.47%
115,894
0%
04/30/2018
DFA US Small Cap Portfolio
760,034
0.47%
303,981
0%
04/30/2018
Fidelity Spartan Extended Market Index Fund
565,434
0.35%
0
0%
07/31/2018
Schwab US Small Cap ETF
403,454
0.25%
0
0%
09/06/2018
| Address |
Perryville III Building
Hampton New Jersey 08827
United States
|
|
Employees
|
- |
| Website |
http://www.celldex.com |
| Updated |
09/14/2018 |
| Celldex Therapeutics, Inc. engages in the research, development, and manufacture of biopharmaceutical products. Its portfolio includes therapeutic antibodies, antibody drug conjugates, vaccines, and immune system modulators. The company's drug candidates include Glembatumumab vedotin, Varlilumab, CDX-1401, CDX-301, and Rintega. |
